US Stock MarketDetailed Quotes
ACTU Actuate Therapeutics
- 8.680
- -0.320-3.56%
Close Nov 27 16:00 ET
169.53MMarket Cap-5957P/E (TTM)
9.340High8.600Low54.10KVolume9.340Open9.000Pre Close475.30KTurnover1.93%Turnover RatioLossP/E (Static)19.53MShares10.16252wk High31.68P/B24.30MFloat Cap5.51052wk Low--Dividend TTM2.80MShs Float10.162Historical High--Div YieldTTM8.22%Amplitude5.510Historical Low8.785Avg Price1Lot Size
About Actuate Therapeutics Company
Actuate Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing therapeutics which target cancers and neurodegenerative diseases. It offers treatment for cancer and inflammatory diseases. It focuses on developing elraglusib. The company was founded by Andrew P. Mazar on January 16, 2015 and is headquartered in Fort Worth, TX.
Company Profile
SymbolACTU
Company NameActuate Therapeutics
Listing DateAug 13, 2024
Issue Price8.00
Founded2015
CEOMr. Daniel M. Schmitt
MarketNASDAQ
Employees10
Fiscal Year Ends12-31
Address1751 River Run,Suite 400
CityFort Worth
ProvinceTexas
CountryUnited States of America
Zip Code76107
Phone1-817-887-8455
Company Executives
- Name
- Position
- Salary
- Daniel M. Schmitt
- President, Chief Executive Officer and Director
- 520.00K
- Paul J. Lytle
- Chief Financial Officer and Principal Accounting Officer
- --
- Dr. Andrew P. Mazar, PhD
- Chief Operating Officer
- 666.11K
- Dr. Aaron G.L. Fletcher, PhD
- Chairman of the Board
- 23.29K
- Leslie W. Kreis, Jr
- Independent Director
- 23.29K
- Jason A. Keyes
- Independent Director
- --
- Dr. Roger Sawhney
- Independent Director
- --
- Todd S. Thon
- Independent Director
- 23.29K
- Amy L. Ronneberg
- Independent Director
- --
- Dr. Dan Zabrowski, PhD
- Independent Director
- 23.29K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
